Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Darotropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 1.00 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darotropium SCHEMBL29355152 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL140648 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL140647 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL29504618 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL3682091 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL16781068 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL3682092 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL146665 | 0.97 | CHRM3 (0.94) | CHRM3CHRM2CHRM1 | |
| Darotropium SCHEMBL146666 | 0.97 | CHRM3 (0.94) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL4631510 | 0.94 | CHRM3 (0.90) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10105316-B2 | Inhalation compositions comprising muscarinic receptor antagonist | Arven llac Sanayi Ve Ticaret A.S. (TR) | 2018-10-23 | — | — | US | disclosed |
| US-20150157567-A1 | INHALATION COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2015-06-11 | — | — | US | disclosed |
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA UK LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8969350-B2 | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient | ASTRAZENECA AB (SE) | 2015-03-03 | — | — | US | disclosed |
| WO-2014007773-A1 | COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST AND SORBITOL | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014007769-A1 | COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST AND GLUCOSE ANHYDROUS | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2014-01-09 | — | — | WO | disclosed |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | ASTRAZENECA UK LIMITED (GB) | 2012-02-02 | — | — | US | disclosed |
| US-20100261690-A1 | NOVEL COMBINATIONS | ASTRAZENECA R&D (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10105316-B2 | Inhalation compositions comprising muscarinic receptor antagonist | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885CHRM2 2/4885CHRM1 5/4885 |
| US-20100261690-A1 | NOVEL COMBINATIONS | ADRB2, NR3C2, GRK4 | CHRM3 21/4885CHRM2 33/4885CHRM1 150/4885 |
| US-20150157567-A1 | INHALATION COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885CHRM2 2/4885CHRM1 5/4885 |
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | NR3C2, GRK4, PTGER2 | CHRM3 629/4885CHRM2 1106/4885CHRM1 1212/4885 |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | NR3C2, ARRB1, GRK4 | CHRM3 654/4885CHRM2 1149/4885CHRM1 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.